Thus, developing a therapeutic strategy that focuses on preventing mutant TGFBIp deposition by reducing its expression and/or increasing its degradation is likely to be achieved in treatment of TGFBI-related CDs. Here, TGFBI is linked to cerebral creatine deficiency syndrome.